To assess associations between improvements in neuropsychiatric symptoms (NPS) and neurocognitive change in patients with Alzheimer’s disease (AD) during treatment using the Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer Disease (CATIE-AD) dataset.
Methods:
AD outpatients with NPS who needed pharmacological treatment (n = 421) were followed up with antipsychotics, citalopram, or placebo for up to 36 weeks (mean±SD = 252±52 days). The study aim was to investigate associations between improvement in each NPS evaluating scale (by Clinical Global Impression of Change [CGI-C], Neuropsychiatric Inventory [NPI], or Brief Psychiatric Scale [BPRS]) at endpoint (week 36 or early termination [ET], n = 340) and neurocognitive change (change score in the Mini-Mental State Examination [MMSE] between endpoint and baseline during the treatment). Multiple logistic regression analyses were performed on the associations between each NPS improvement and neurocognitive change as well as socio-clinico-demographic variables of interest.
Results:
At endpoint, NPS improvement rates were 76.1%, 70.8%, and 58.1% in CGI-C, NPI, and BPRS, respectively, while MMSE score change was –2.3±3.8. NPS improvement was significantly related to more severe psychotic symptoms at baseline and preserved levels of neurocognition (smaller MMSE score change) among several variables.
Conclusions:
Our findings suggested that neurocognitive preservation may be associated with attaining optimal benefits from any treatment against NPSs in a longitudinal treatment course of patients with AD.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
2.
de Vugt ME, StevensF, AaltenP, LousbergR, JaspersN, VerheyFR (2005) A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. Int Psychogeriatr17, 577–589.
3.
LövheimH, SandmanPO, KarlssonS, GustafsonY (2008) Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. Int Psychogeriatr20, 777–789.
4.
MegaMS, CummingsJL, FiorelloT, GornbeinJ (1996) The spectrum of behavioral changes in Alzheimer’s disease. Neurology46, 130–135.
5.
PiccininniM, Di Carlo A, BaldereschiM, ZaccaraG, InzitariD (2005) Behavioral and psychological symptoms in Alzheimer’s disease: Frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord19, 276–281.
6.
SchneiderLS, TariotPN, DagermanKS, DavisSM, HsiaoJK, IsmailMS, LebowitzBD, LyketsosCG, RyanJM, StroupTS, SultzerDL, WeintraubD, LiebermanJA, CATIE-AD Study Group (2006) Effectiveness of atypical Antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med355, 1525–1538.
7.
NagataT, NakajimaS, ShinagawaS, PlitmanE, Graff-GuerreroA, MimuraM, NakayamaK (2016) Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer’s disease needing interventional treatment: Analysis of the CATIE-AD study. Int J Geriatr Psychiatry232, 1264–1271.
8.
GauthierS, VellasB, FarlowM, BurnD (2006) Aggressive course of disease in dementia. Alzheimers Dement2, 210–207.
9.
RopackiSA, JesteDV (2005) Epidemiology of and risk factors for psychosis of Alzheimer’s disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry162, 2022–2030.
10.
NagataT, NakajimaS, ShinagawaS, PlitmanE, NakayamaK, Graff-GuerreroA, MimuraM (2017) Baseline predictors of antipsychotic treatment continuation and response at week 8 in patients with Alzheimer’s disease with psychosis or aggressive symptoms: An analysis of the CATIE-AD study. J Alzheimers Dis60, 263–272.
11.
SchneiderLS, TariotPN, LyketsosCG, DagermanKS, DavisKL, DavisS, HsiaoJK, JesteDV, KatzIR, OlinJT, PollockBG, RabinsPV, RosenheckRA, SmallGW, LebowitzB, LiebermanJA (2001) National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer disease trial methodology. Am J Geriatr Psychiatry9, 346–360.
12.
CummingsJL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology48(5 Suppl 6), S10–S16.
13.
IsmailZ, EmeremniCA, HouckPR, MazumdarS, RosenJ, RajjiTK, PollockBG, MulsantBH (2013) A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. Am J Geriatr Psychiatry21, 78–87.
14.
LeuchtS, KaneJM, EtschelE, KisslingW, HamannJ, EngelRR (2006) Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology31, 2318–2325.
15.
SchneiderLS, OlinJT, DoodyRS, ClarkCM, MorrisJC, ReisbergB, SchmittFA, GrundmanM, ThomasRG, FerrisSH (1997) Validity and reliability of the Alzheimer’s disease cooperative study-clinical global impression of change. The Alzheimer’s disease cooperative study. Alzheimer Dis Assoc Disord11(Suppl 2), S22–S32.
16.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
17.
GalaskoD, BennettD, SanoM, ErnestoC, ThomasR, GrundmanM, FerrisS (1997) An inventory to assess Activities of Daily Livingfor clinical trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord11(Suppl 2), S33–S39.
18.
LyketsosCG, GalikE, SteeleC, SteinbergM, RosenblattA, WarrenA, SheppardJM, BakerA, BrandtJ (1999) The “General Medical Health Rating” (GMHR): A bedside global rating of medical comorbidity in patients with dementia. J Am Geriatr Soc47, 487–491.
19.
ZaritSH, ReeverCH, Bach-PetersonJ (1980) Relatives of the impaired elderly: Correlates of feeling burden. Gerontologist20, 649–655.
20.
WinbladB, WimoA, EngedalK, SoininenH, VerheyF, WaldemarG, WetterholmAL, HaglundA, ZhangR, SchindlerR (2006) 3-year study of donepezil therapy in Alzheimer’s disease: Effects of early and continuous therapy. Dement Geriatr Cogn Disord21, 353–363.
21.
BaroccoF, SpallazziM, ConcariL, GardiniS, PelosiA, CaffarraP (2017) The progression of Alzheimer’s disease: Are fast decliners really fast? A four-year follow-up. J Alzheimers Dis57, 775–786.
22.
ClarkCM, SheppardL, FillenbaumGG, GalaskoD, MorrisJC, KossE, MohsR, HeymanA (1999) Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: A clinical perspective of data from the Consortium to Establish a Registry for Alzheimer’s disease. Arch Neurol56, 857–862.
PorsteinssonAP, DryeLT, PollockBG, DevanandDP, FrangakisC, IsmailZ, MaranoC, MeinertCL, MintzerJE, MunroCA, PeltonG, RabinsPV, RosenbergPB, SchneiderLS, ShadeDM, WeintraubD, YesavageJ, LyketsosCG, CitAD Research Group (2014) Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA311, 682–691.
25.
DevanandDP, PeltonGH, CunqueiroK, SackeimHA, MarderK (2011) A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. Int J Geriatr Psychiatry26, 937–943.
26.
DevanandDP, MintzerJ, SchultzSK, AndrewsHF, SultzerDL, de la Pena D, GuptaS, ColonS, SchimmingC, PeltonGH, LevinB (2012) Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med367, 1497–1507.
27.
RouchI, PonganE, TrombertB, FabreF, AugusteN, SellierC, FreulonM, JacquelineS, FedericoD, MouchouxC, Martin-GaujardG, Krolak-SalmonP, LaurentB, DoreyJM (2017) One-year evolution of behavioral and psychological symptoms of dementia in patients initially hospitalized in cognitive behavioral units: The EVITAL prospective cohort. J Alzheimers Dis57, 147–155.
28.
EmanuelJE, LopezOL, HouckPR, BeckerJT, WeamerEA, Demichele-SweetMA, KullerL, SweetRA (2011) Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry19, 160–168.
29.
PetersME, SchwartzS, HanD, RabinsPV, SteinbergM, TschanzJT, LyketsosCG (2015) Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: The Cache County Dementia Progression Study. Am J Psychiatry172, 460–465.
30.
PoulinSP, BergeronD, DickersonBC, Alzheimer’s Disease Neuroimaging Initiative (2017) Risk factors, neuroanatomical correlates, and outcome of neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis60, 483–493.
31.
HsuTJ, TsaiHT, HwangAC, ChenLY, ChenLK (2017) Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia. Geriatr Gerontol Int17(Suppl1), 28–35.
32.
HerrmannN, GauthierS, LysyPG (2007) Clinical practice guidelines for severe Alzheimer’s disease. Alzheimers Dement3, 385–397.
33.
HowardRJ, JuszczakE, BallardCG, BenthamP, BrownRG, BullockR, BurnsAS, HolmesC, JacobyR, JohnsonT, KnappM, LindesayJ, O’BrienJT, WilcockG, KatonaC, JonesRW, DeCesareJ, RodgerM, CALM-AD Trial Group (2007) Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med357, 1382–1392.
BlackwoodNJ, HowardRJ, BentallRP, MurrayRM (2001) Cognitive neuropsychiatric models of persecutory delusions. Am J Psychiatry158, 527–539.
36.
GedaYE, SchneiderLS, GitlinLN, MillerDS, SmithGS, BellJ, EvansJ, LeeM, PorsteinssonA, LanctôtKL, RosenbergPB, SultzerDL, FrancisPT, BrodatyH, PadalaPP, OnyikeCU, OrtizLA, Ancoli-IsraelS, BliwiseDL, MartinJL, VitielloMV, YaffeK, ZeePC, HerrmannN, SweetRA, BallardC, KhinNA, AlfaroC, MurrayPS, SchultzS, LyketsosCG, Neuropsychiatric Syndromes Professional Interest Area of ISTAART (2013) Neuropsychiatric symptoms in Alzheimer’s disease: Past progress and anticipation of the future. Alzheimers Dement9, 602–608.
37.
MartyrA, ClareL (2012) Executive function and activities of daily living in Alzheimer’s disease: A correlational meta-analysis. Dement Geriatr Cogn Disord33, 189–203.
38.
CarbonM, CorrellCU (2014) Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci16, 505–524.
39.
VigenCL, MackWJ, KeefeRS, SanoM, SultzerDL, StroupTS, DagermanKS, HsiaoJK, LebowitzBD, LyketsosCG, TariotPN, ZhengL, SchneiderLS (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: Outcomes from CATIE-AD. Am J Psychiatry168, 831–839.
